Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life.
Therapies for benign prostatic hyperplasia (BPH) may either improve or exacerbate sexual function with an ensuing impact on quality of life. Here we review a total of 73 papers on medical therapies for BPH with a focus on the effects of different pharmacological agents on sexual function. For example, certain alpha(1)-adrenergic receptor blockers may improve erectile function; however, ejaculatory dysfunction with one of these agents, tamsulosin, occurs at a rate of 4-18%, rising to 30% with long-term use. In addition, treatment with the 5 alpha-reductase inhibitor finasteride is associated with problems of ejaculation (2.1-7.7%), erection (4.9-15.8%), and libido (3.1-5.4%). Such significant and undesirable complications in relation to sexual function produce a well-documented negative impact on quality of life. Thus, optimal treatment for men with BPH requires the use of agents that demonstrate efficacy and safety with fewer sexual side effects.
Carbone
D J
DJ
Department of Urology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157, USA. dcarbone@wfubmc.edu
Hodges
S
S
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000009:adverse effects*; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects*; D003075:Coitus; D004542:Ejaculation / Q000187:drug effects; D006801:Humans; D007989:Libido / Q000187:drug effects; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D011788:Quality of Life; D012735:Sexual Dysfunction, Physiological / Q000209:etiology; D014570:Urologic Diseases / Q000209:etiology
D000317:Adrenergic alpha-Antagonists; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase